The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg. This product is expected to be launched in Q1 FY16-17.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation. Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. The approved product has an estimated market size of US$ 26.7 million forthe twelve months ending January 2016 according to IMS.
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.
Aurobindo Pharma Ltd is currently trading at Rs. 718.15, down by Rs. 27.55 or 3.69% from its previous closing of Rs. 745.7 on the BSE.
The scrip opened at Rs. 745.7 and has touched a high and low of Rs. 746.8 and Rs. 709.45 respectively. So far 1304564(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 43636.1 crore.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.5 on 30-Dec-2015 and a 52 week low of Rs. 570.5 on 27-Mar-2015. Last one week high and low of the scrip stood at Rs. 761.3 and Rs. 736.5 respectively.
The promoters holding in the company stood at 53.9 % while Institutions and Non-Institutions held 35.24 % and 10.86 % respectively.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation. Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. The approved product has an estimated market size of US$ 26.7 million forthe twelve months ending January 2016 according to IMS.
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.
Aurobindo Pharma Ltd is currently trading at Rs. 718.15, down by Rs. 27.55 or 3.69% from its previous closing of Rs. 745.7 on the BSE.
The scrip opened at Rs. 745.7 and has touched a high and low of Rs. 746.8 and Rs. 709.45 respectively. So far 1304564(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 43636.1 crore.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.5 on 30-Dec-2015 and a 52 week low of Rs. 570.5 on 27-Mar-2015. Last one week high and low of the scrip stood at Rs. 761.3 and Rs. 736.5 respectively.
The promoters holding in the company stood at 53.9 % while Institutions and Non-Institutions held 35.24 % and 10.86 % respectively.
No comments:
Post a Comment